Chi-Un Choe1, Susanne Lezius2, Kathrin Cordts3,4, Christian Gerloff5, Rainer H Böger3,4, Edzard Schwedhelm3,4, Peter J Grant6. 1. Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. cchoe@uke.de. 2. Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3. Institute of Clinical Pharmacology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 4. DZHK (Deutsches Zentrum für Herz-Kreislauf-Forschung e.V.), partner site Hamburg/Kiel/Lübeck, Hamburg, Germany. 5. Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. 6. Leeds Institute of Cardiovascular and Metabolic Medicine, Leeds, UK.
Abstract
BACKGROUND: Guanidino compounds, including asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and L-homoarginine (hArg), have been associated with cardio- and cerebrovascular events and risk. We aimed to study if low hArg/ADMA and hArg/SDMA ratios are associated with mortality and outcome after stroke. METHODS: In two prospective cohorts of acute stroke patients from Germany and the UK, we analyzed hArg, ADMA, and SDMA to determine hArg/ADMA and hArg/SDMA ratios. The guanidino compound levels were associated with mortality, adverse events, and neurological impairment, i.e., National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS). RESULTS: During 7.4 years, high hArg/ADMA and hArg/SDMA ratios were both associated with a reduction in all-cause mortality in patients with ischemic stroke in a UK stroke cohort (hArg/ADMA: hazard ratio (HR) 0.75 [95% confidence interval (CI) 0.62-0.92]; n = 394; P = 0.006; hArg/SDMA: HR 0.68 [0.54-0.85]; n = 394; P = 0.001). In a German stroke cohort, patients with high hArg/SDMA ratio experienced fewer adverse events compared with those with low hArg/SDMA ratios within 30 days after stroke (HR 0.73 [0.57-0.92]; n = 135; P = 0.009), whereas hArg/ADMA was not predictive. Furthermore, hArg/SDMA ratios inversely correlated with the degree of neurological impairment (NIHSS) (r = - 0.27; P = 0.001; n = 138). Lower hArg/SDMA ratios were also found in dependent (mRS 3-6) compared with independent patients (mRS < 3; P = 0.007; n = 138), whereas hArg/ADMA did not. CONCLUSION: These results from two prospective stroke studies reveal that hArg/SDMA ratio could prove a valuable blood-based biomarker to discriminate patients with poor short- and long-term outcome, increased neurological impairment, and severe disability after stroke.
BACKGROUND:Guanidino compounds, including asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and L-homoarginine (hArg), have been associated with cardio- and cerebrovascular events and risk. We aimed to study if low hArg/ADMA and hArg/SDMA ratios are associated with mortality and outcome after stroke. METHODS: In two prospective cohorts of acute strokepatients from Germany and the UK, we analyzed hArg, ADMA, and SDMA to determine hArg/ADMA and hArg/SDMA ratios. The guanidino compound levels were associated with mortality, adverse events, and neurological impairment, i.e., National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS). RESULTS: During 7.4 years, high hArg/ADMA and hArg/SDMA ratios were both associated with a reduction in all-cause mortality in patients with ischemic stroke in a UK stroke cohort (hArg/ADMA: hazard ratio (HR) 0.75 [95% confidence interval (CI) 0.62-0.92]; n = 394; P = 0.006; hArg/SDMA: HR 0.68 [0.54-0.85]; n = 394; P = 0.001). In a German stroke cohort, patients with high hArg/SDMA ratio experienced fewer adverse events compared with those with low hArg/SDMA ratios within 30 days after stroke (HR 0.73 [0.57-0.92]; n = 135; P = 0.009), whereas hArg/ADMA was not predictive. Furthermore, hArg/SDMA ratios inversely correlated with the degree of neurological impairment (NIHSS) (r = - 0.27; P = 0.001; n = 138). Lower hArg/SDMA ratios were also found in dependent (mRS 3-6) compared with independent patients (mRS < 3; P = 0.007; n = 138), whereas hArg/ADMA did not. CONCLUSION: These results from two prospective stroke studies reveal that hArg/SDMA ratio could prove a valuable blood-based biomarker to discriminate patients with poor short- and long-term outcome, increased neurological impairment, and severe disability after stroke.
Authors: M Odette Gore; Nicole Lüneburg; Edzard Schwedhelm; Colby R Ayers; Maike Anderssohn; Amit Khera; Dorothee Atzler; James A de Lemos; Peter J Grant; Darren K McGuire; Rainer H Böger Journal: Arterioscler Thromb Vasc Biol Date: 2013-09-05 Impact factor: 8.311
Authors: Chi-un Choe; Dorothee Atzler; Philipp S Wild; Angela M Carter; Rainer H Böger; Francisco Ojeda; Olga Simova; Malte Stockebrand; Karl Lackner; Christine Nabuurs; Bart Marescau; Thomas Streichert; Christian Müller; Nicole Lüneburg; Peter P De Deyn; Ralf A Benndorf; Stephan Baldus; Christian Gerloff; Stefan Blankenberg; Arend Heerschap; Peter J Grant; Tim Magnus; Tanja Zeller; Dirk Isbrandt; Edzard Schwedhelm Journal: Circulation Date: 2013-09-04 Impact factor: 29.690
Authors: Stefan Pilz; Andreas Meinitzer; Andreas Tomaschitz; Christiane Drechsler; Eberhard Ritz; Vera Krane; Christoph Wanner; Bernhard O Boehm; Winfried März Journal: Heart Date: 2011-05-10 Impact factor: 5.994
Authors: Martin Bahls; Nele Friedrich; Dorothee Atzler; Stephan B Felix; Matthias A Nauck; Rainer H Böger; Henry Völzke; Edzard Schwedhelm; Marcus Dörr Journal: PLoS One Date: 2015-06-22 Impact factor: 3.240